Decitabine

Catalog No.S1200 Synonyms: Deoxycytidine

Decitabine Chemical Structure

Molecular Weight(MW): 228.21

Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).

Size Price Stock Quantity  
In DMSO USD 155 In stock
USD 90 In stock
USD 170 In stock
USD 320 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • (A) and (B) SW1116 and LOVO cells were plated, treated for 48 h with decitabine (DAC) and gefitinib (GEF) either alone or in combination, and the expression levels of AKT, mTOR, S6K, and phosphorylation were determined by Western blot analysis as described under Methods. Expression of β-actin served as a loading control. The data are representative of three independent experiments.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

    (A) and (B) SW1116 and LOVO cells were cultured in control conditions (DMSO) or in the presence of the indicated concentrations of decitabine (DAC) and gefitinib (GEF), alone or in combination, for 48 h. And then cells were stained with Annexin V-FITC and propidium iodide (PI) and analyzed by flow cytometry. This experiment was done in triplicate and representative diagrams of Annexin V-FITC assays are shown.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

  • Leuk Res 2014 38(3), 402-10. Decitabine purchased from Selleck.

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).
Targets
DNA methylation [1]
(HL-60, KG1a cells)
In vitro

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 M4XJZmZ2dmO2aX;uJGF{e2G7 M{\leFAvPcLizszN NFfXcG8zPCCq NVnDfW46f2G2ZYK= NELXUo5ud2S3bHH0[ZMhfGinIHflcoUh\XiycnXzd4lwdiCxZjDNRWdGNUFibXXtZoVzew>? MnHXNlUyOjNyOEK=
Eca109 MkDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;XUFAvPS9{LkWvOUDPxE1? M2nuZVI1NzR6L{eyJIg> NEX3Z3V4[XSnch?= MWDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJIRwe2VvIHHu[EB1cW2nLTDk[ZBmdmSnboSgcYFvdmW{ MXeyOVEzOzB6Mh?=
Eca109 Mo\vSpVv[3Srb36gRZN{[Xl? M3jVU|AvPcLizszN MV22M|EzNzJ2IHi= NVX6NY9Lf2G2ZYK= NEPMWVVqdmirYnn0d{Bk\WyuIH3p[5JifGmxbtMg NYCxdphNOjVzMkOwPFI>
Eca109 M4DZfWZ2dmO2aX;uJGF{e2G7 NWjYVlQ6OC53wrFOwG0> NH22RWEzPCCq MnHVe4F1\XJ? MX3pcohq[mm2czDj[YxtKGmwdnHzbY9v M1fNXVI2OTJ|MEiy
Eca109 M4jlSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX[2Z5JCOC53wrFOwG0> NXu5S|hYOjRiaB?= NUL1bYk3f2G2ZYK= NEC0dWdqdmS3Y3XzJGczN01iYYLy[ZN1KGmwIITo[UBk\WyuIHP5Z4xm NGHwUW0zPTF{M{C4Ni=>
Eca109 M3PLSmZ2dmO2aX;uJGF{e2G7 MkHENE42NzFizszN MlXUNlQhcA>? M3jp[pdifGW{ M1fyfYRm[3KnYYPld{BmgHC{ZYPzbY9vKG:oIF7GMe67SjJiYX7kJG1OWDJ? MUSyOVEzOzB6Mh?=
SW1116  NXz6WJFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvGU|Z3OC53L{GvNk82KM7:TR?= MnK5OFghcA>? MnrXSG1UVw>? MUXlcohidmOnczD0bIUhT2WoaYTpcoljKGmwZIXj[YQh[2WubDDpcohq[mm2aX;u NF;F[ZAzPDh5NEK4Oi=>
LOVO NWnk[GRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1O2b|AvPS9zL{KvOUDPxE1? MY[0PEBp NYO3d2VTTE2VTx?= MWLlcohidmOnczD0bIUhT2WoaYTpcoljKGmwZIXj[YQh[2WubDDpcohq[mm2aX;u NV;0SYJlOjR6N{SyPFY>
SW1116  NGLsXXdHfW6ldHnvckBCe3OjeR?= NH30d4IyOCEQvF2= NWf5XXpNPDhiaB?= NFPlSXdFVVOR NH3vTGFqdmO{ZXHz[ZMhfGinIHXm[oVkfGm4ZTDheEBqdmirYnn0bY5oKEGNVDDhcoQhdVSRUjDzbYdv[WyrbnegdIF1cHejeYOgZ49u[mmwZXSge4l1cCCpZX\peIlvcWJ? Ml3lNlQ5PzR{OE[=
LOVO Mn3mSpVv[3Srb36gRZN{[Xl? MVuxNEDPxE1? MXe0PEBp NYTpNXYzTE2VTx?= NH7OOnlqdmO{ZXHz[ZMhfGinIHXm[oVkfGm4ZTDheEBqdmirYnn0bY5oKEGNVDDhcoQhdVSRUjDzbYdv[WyrbnegdIF1cHejeYOgZ49u[mmwZXSge4l1cCCpZX\peIlvcWJ? NFjOO2gzPDh5NEK4Oi=>
SW1116  MUfBdI9xfG:|aYOgRZN{[Xl? NXL6NG1pOTBizszN MmnuOFghcA>? M{XQW2ROW09? MVjlcohidmOnczDH[YZqfGmwaXKtbY5lfWOnZDDhdI9xfG:|aYO= MYOyOFg4PDJ6Nh?=
LOVO MXXBdI9xfG:|aYOgRZN{[Xl? M1fTWFExKM7:TR?= NXnzOppDPDhiaB?= M3jaSmROW09? NFPW[IRmdmijbnPld{BI\W[rdHnubYIucW6mdXPl[EBieG:ydH;zbZM> NWTDc2tlOjR6N{SyPFY>
RPMI-8226 NV3nR3VKSXCxcITvd4l{KEG|c3H5 NHLOWWsyNzJizszN MVe0PE84Oi97NjDo MUnEUXNQ MVrpcoR2[2W|IHPlcIwh[XCxcITvd4l{ M3\qRVI1QDN|MUC4
OPM-2  NIXFNHpCeG:ydH;zbZMhSXO|YYm= NFXsPGMyNzJizszN NEK2[WY4Oi97Nj:xNlAhcA>? MUnEUXNQ MXnpcoR2[2W|IHPlcIwh[XCxcITvd4l{ M1ewb|I1QDN|MUC4
JJN3  MWLBdI9xfG:|aYOgRZN{[Xl? MknMNE42NzFizszN NEn5ZZMzPC92ODDo MWjEUXNQ NH;zbZBqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MoHzNlQ5OzNzMEi=
NCI-H929  MlK0RZBweHSxc3nzJGF{e2G7 NVzXeFZTOS9{IN88US=> NXf2cFE6PzJxOU[vNVIxKGh? NHyydoNFVVOR NX;UcpFLcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MUCyOFg{OzFyOB?=
RPMI-8226 NXj2bmY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPCTo5JOS9{IN88US=> MYmyOE81QC95MjDo MVXEUXNQ NULkOIFw[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= MmD0NlQ5OzNzMEi=
OPM-2  MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHXSYc3OS9{IN88US=> M37J[lI1NzR6L{eyJIg> NYTX[FNkTE2VTx?= NHXK[WFi\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?= NGLkXnYzPDh|M{GwPC=>
JJN3  MoP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmK5NE42NzFizszN NEC5PWYzPC92OD:3NkBp M{DK[WROW09? M1q5eoFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 MYWyOFg{OzFyOB?=
NCI-H929  M2\KWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUixM|Ih|ryP MmDGNlQwPDhxN{KgbC=> M{Dhe2ROW09? MnL0ZYZn\WO2czDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKG6nZ3H0bZZmdHl? NHL2d|czPDh|M{GwPC=>
HeLa MmHaT4lv[XOnIFHzd4F6 M1jWZ2tqRTFyMEFihLM2ODByIN88UUBnd3JiaFXOWFE> NV3LeVJqOjR5OECwPVg>
HeLa M2XnUWtqdmG|ZTDBd5NigQ>? MX7LbV02NjZiwsGgNE42KM7:TTDmc5IhcEWQVEK= M2HWVlI1PzhyMEm4
HeLa MUXLbY5ie2ViQYPzZZk> MljHT4k:OjFwNjFCtUA{NjBizszNJIZweiCqQ17UNS=> NEjyUJgzPDd6MEC5PC=>
HeLa M{nkcWtqdmG|ZTDBd5NigQ>? MkL3T4k:OTRwNDFCtUA1NjZizszNJIZweiCqQ17UNy=> MYiyOFc5ODB7OB?=
NB4 MkfMSpVv[3Srb36gRZN{[Xl? NYizdlBMOi53L{WvO{42NzFyIN88US=> NH;iblkzPCCq NXz5bZdNTE2VTx?= NUfpbGpzcW6lcnXhd4ViKHSqZTDlfJBz\XO|aX;uJI9nKHC{ZXP1dpNweiCvaWKtNVI2[Q>? MWOyOFQ5PDh5MB?=
CD4+ CD25− T  NHj0[JdHfW6ldHnvckBCe3OjeR?= MXGxM|Uh|ryP NI\ub5hz\WS3Y3XTJIdtd2KjbDDEUmEhdWW2aInsZZRqd25? MXyyOFQ4PjN4MB?=
BV-173 NYf4bo9YSXCxcITvd4l{KEG|c3H5 MorPNE4zPS9yLkWvNE44PS9zIN88US=> M{TWNVQ5Nzd{L{m2JIg> NWDOe4VpyqCSQmO= MorObY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy NEPXUXozPDR{M{[xNy=>
ML-1 NIHLbpJCeG:ydH;zbZMhSXO|YYm= NGPBcWUxNjJ3L{CuOU8xNjd3L{Gg{txO MUK0PE84Oi97NjDo M3jpc:KhWEKV M3LFSIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> NVfHOJM{OjR2MkO2NVM>
HL-60 MX7BdI9xfG:|aYOgRZN{[Xl? MYOwMlI2NzBwNT:wMlc2NzFizszN MoTyOFgwPzJxOU[gbC=> MmnBxsBRSlN? NWjvdGNXcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz MUSyOFQzOzZzMx?=
KG-1a NEiz[W9CeG:ydH;zbZMhSXO|YYm= NWjvT4FQOC5{NT:wMlUwOC55NT:xJO69VQ>? NIrmdpM1QC95Mj:5OkBp Mn;pxsBRSlN? NHPlblRqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> MXWyOFQzOzZzMx?=
BV-173 NVyxSlZ{TnWwY4Tpc44hSXO|YYm= MUGyOVAwPTBybl2= NXXyNlM2PDhiaB?= NHL5ZXbDqFCEUx?= M4\ZcIlv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= NHfvWGkzPDR{M{[xNy=>
CEM MnjaSpVv[3Srb36gRZN{[Xl? NWXiWJM2OjVyL{WwNI5O MnnJOFghcA>? NYe0bmliyqCSQmO= NGDkPGtqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W= NGixeXMzPDR{M{[xNy=>
HL-60 MVzGeY5kfGmxbjDBd5NigQ>? NYKxb3lFOjVyL{WwNI5O NUL2VZhTPDhiaB?= NYrvZpZVyqCSQmO= NGj6VlVqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W= M2nwNlI1PDJ|NkGz
ML-1 NFXQVXlHfW6ldHnvckBCe3OjeR?= NWTI[2xkOjVyL{WwNI5O NEjXXY41QCCq NYTDN2VyyqCSQmO= MVjpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? NVe1dlFxOjR2MkO2NVM>
DLD-1 MlW3SpVv[3Srb36gRZN{[Xl? MUWyOVAwPTBybl2= M2TEOlQ5KGh? MXJCpHBDWw>? NWLCUHh6\G9ibn;0JIlv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= MnPENlQ1OjN4MUO=
HCT-116 MorKSpVv[3Srb36gRZN{[Xl? NEf3bZIzPTBxNUCwcm0> MWK0PEBp NFXoNpfDqFCEUx?= M1;rPIRwKG6xdDDpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? NGfyNVIzPDR{M{[xNy=>
U937-A/E-9/14/18  M3\2bGFxd3C2b4Ppd{BCe3OjeR?= MnH5NE4xOS9yLkGvNU8yOCEQvF2= NGPnb4I1QCCq NYrpcmxMcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M1fvSlI1OzByNEW2
HT29 NFnDfJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDCbJRUPzJiaB?= MkHyTWM2OD1zNECwxtEyPzlizszN Moj6NlQyPzJyNkG=
SW48 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrnO|IhcA>? MX7JR|UxRTF3LkNCtVYvOiEQvF2= MV:yOFE4OjB4MR?=
HCT116 MnPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrMO|IhcA>? NIT2W45KSzVyPUGuO:KyOC52IN88US=> Mme4NlQyPzJyNkG=
HepG2 MmDXSpVv[3Srb36gRZN{[Xl? Mnv2NE42NzFizszN Mn;UNlQhcA>? Mmj0SG1UVw>? MXj1dE1z\We3bHH0[YQhfGinIILlcIF1cX[nIF;DWG4zKG2UTlGgZY5lKHC{b4TlbY4h\XiycnXzd4lwdg>? NF7ZOWczPDF2Nki3OC=>
LS174T MlTmSpVv[3Srb36gRZN{[Xl? MljhNE42NzFizszN MXGyOEBp M{XHN2ROW09? NHfLO5lt\WGmIITvJIFvKGmwY4LlZZNmKG:oIF;DWG4zKGyndnXsdy=> NIjicGwzPDF2Nki3OC=>
HepG2 MV\BdI9xfG:|aYOgRZN{[Xl? MnHQNU8yOC9zMECg{txO M{H6NVch\A>? MXTEUXNQ NEG0eoJqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M12wSVI1OTR4OEe0
LS174T MYTBdI9xfG:|aYOgRZN{[Xl? NVvxVXVCOS9zMD:xNFAh|ryP NVTrSGNjPyCm MlXTSG1UVw>? MWfpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NISyZ|UzPDF2Nki3OC=>
QBC-939 MUTBdI9xfG:|aYOgRZN{[Xl? MXuxM|ExNzFyMDFOwG0> MXi3JIQ> MoO2SG1UVw>? NEe2ellqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NXvjco52OjRzNE[4O|Q>
U251 Mk\qRZBweHSxc3nzJGF{e2G7 MnXrNU8yOC9zMECg{txO M4D0blch\A>? NVPkfFZETE2VTx?= NWXNWVlLcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M4PIPVI1OTR4OEe0
HL-60 NX\ybmZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\TfVEyKM7:TR?= M3ztSlQ5KGh? MmWwbY5kemWjc3XzJGczNXCqYYPlJINmdGxiZoLhZ5Rqd25? NXn1NZdSOjRyMECzNlQ>
MDA‑MB‑453 NXKwd25FTnWwY4Tpc44hSXO|YYm= MXGwMlIwOSEQvF2= MUW3NkBp M2XrPYNifXOnczDy[U1mgHC{ZYPzbY9vKG:oIHPsZZVlcW8EoEJCpC=> M4e4PFI{QDR2MkK4
HCC1569 NVfKTGhuTnWwY4Tpc44hSXO|YYm= NGnnSmsxNjJxMTFOwG0> MkL0O|IhcA>? MXfjZZV{\XNicnWt[ZhxemW|c3nvckBw\iClbHH1[IlvyqBzwrC= NHzjcHUzOzh2NEKyPC=>
BT‑474 Mn;oSpVv[3Srb36gRZN{[Xl? MYSwMlIwOSEQvF2= MkXBO|IhcA>? NHvPN2Fk[XW|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA> NGjXem0zOzh2NEKyPC=>
AGS NFjFendCeG:ydH;zbZMhSXO|YYm= NIr3SYg2NzFyL{KwM|UxKM7:TR?= M2\EcFQ5yqCqwrC= NVrlOHdITE2VTx?= MXzpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdIpCpC=> NIK0UFIzOzV6Mke4OC=>
A549 M1jt[WFxd3C2b4Ppd{BCe3OjeR?= M33pNFUwOTBxMkCvOVAh|ryP M{G4cVQ5yqCqwrC= M2LZbmROW09? NF7Xe|dqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJnDqA>? M{KzOFI{PTh{N{i0
AGS  NYDkWXZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vMWlUwOTBxMkCvOVAh|ryP MlGwOFjDqGkEoB?= M1WzV2ROW09? NETZe5FqdmS3Y3XzJGczN01icHjhd4Uh[XK{ZYP0xsA> M1eyUFI{PTh{N{i0
Kasumi-1 Mmj2RZBweHSxc3nzJGF{e2G7 M2PYelAvPSEQvF2= M3\D[FQ5yqCqwrC= NHTISFZl\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGOxLYTy[YF1\WRid3n0bEBV\i2QUD3zZy=> MojiNlM1QTN|NEi=
OCI-AML3 NX3JVFl[SXCxcITvd4l{KEG|c3H5 MmPHNk42KM7:TR?= MYC0POKhcMLi MXjk[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JINwNXS{ZXH0[YQhf2m2aDDU[k1PWC2|Yx?= M3[ybVI{PDl|M{S4
MV4-11 M1TZNGFxd3C2b4Ppd{BCe3OjeR?= NGq4XJgzNjVizszN NIrEeYc1QMLiaNMg NVH4W|lu\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSClbz30doVifGWmIIfpeIghXGZvTmCtd4M> NW\sdphlOjN2OUOzOFg>
NK  M2P6[2N6fG:2b4jpeJkhSXO|YYm= MnvoNE4xOi1{MDFOwG0> MWO1JIQ> MVrk[YNz\WG|ZYOgeIhmKGO7dH;sfZRq[yCjY4Tpeol1gSCxZjDOT{Bk\WyuczDheEBqdnSncn3l[IlifGViY3;uZ4VvfHKjdHnvcpMhemW|dXz0bY5oKGmwIHGgWU1{cGGyZXSg[I9{\eLCk4Lld5BwdnOnIHP1dpZm NHXxbHozOzN{OEC4PC=>
NK  NWTJNnJESXCxcITvd4l{KEG|c3H5 NHXVSHYxNjB{LUKwJO69VQ>? MXS1JIQ> Mnvm[IVkemWjc3WgUmsh[2WubDDwdo9tcW[ncnH0bY9vKGGwZDD2bYFjcWyrdImgZZMhfGinIHPvcoNmdnS{YYTpc44hcW6lcnXhd4Vl MVyyN|MzQDB6OB?=
NK  NVrXRnFTTnWwY4Tpc44hSXO|YYm= MmnoNE4xOS1{MDFOwG0> M3zxflUh\A>? M2GybYNifXOnczDofZBwdWW2aInsZZRqd25ib3[gUmsh[2WubIOgbY4h[SCmb4Pl5qCUemW|cH;ud4U> NUHLOJRSOjN|MkiwPFg>
MOLT4/DNR MlTJSpVv[3Srb36gRZN{[Xl? NGXWNXg2KM7:TR?= NHXBUIU1KGR? NX;6[2N1emWmdXPld{BCSkOEMTDtVm5CKGW6cILld5Nqd25? Mn7QNlMxPjB3N{C=
Jurkat/DOX NXy0PZg{TnWwY4Tpc44hSXO|YYm= M2LJOFUh|ryP MkfJOEBl NGX2[HBz\WS3Y3XzJGFDS0JzIH3SUmEh\XiycnXzd4lwdg>? MVKyN|A3ODV5MB?=
MOLT4/DNR MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXO1JO69VQ>? M1rTPVQh\A>? M2fydpJm\HWlZYOgeIhmKEmFNUFCpJZidHWnIH\vdkBl[XWwb4L1ZolkcW5ic3Xud4l1cX[rdIm= MlfwNlMxPjB3N{C=
Jurkat/DOX NUnTWHRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\kdmE2KM7:TR?= NHHJXWI1KGR? MV;y[YR2[2W|IITo[UBKSzVywrD2ZYx2\SCob4Kg[IF2dm:{dXLpZ4lvKHOnboPpeIl3cXS7 NH71NIszOzB4MEW3NC=>
ccRCC  MWrBdI9xfG:|aYOgRZN{[Xl? MWKwMlAyNTFyzszN NXSxOHM4PzJiaB?= NGXVRmRFVVOR MUXoZZMhdWmwaX3hcEBm\m[nY4Sgc44h[2WubDDwdo9tcW[ncnH0bY9v NWj5[HYyOjJ6Mk[0Olc>
TNBC  MXTBdI9xfG:|aYOgRZN{[Xl? NIridYYxNjBzLUGw{txO MnixO|IhcA>? MYPEUXNQ NEHrNYlp[XNibXnubY1idCCnZn\lZ5Qhd25iY3XscEBxem:uaX\ldoF1cW:w MnfGNlI5OjZ2Nke=
A498 MlW5RZBweHSxc3nzJGF{e2G7 NHHBVFcxNjBzLUGw{txO MVW3NkBp MoHvSG1UVw>? M2nTPIlv\HWlZYOgd5lv\XKpaYP0bYMhemW|cH;ud4V{yqC5aYToJJJwdWmmZYDzbY4> MVeyNlgzPjR4Nx?=
KIJ265T MUjBdI9xfG:|aYOgRZN{[Xl? NX3HUIpsOC5yMT2xNO69VQ>? Mnj5O|IhcA>? M3rRV2ROW09? NVv4UlRHcW6mdXPld{B{gW6ncnfpd5Rq[yC{ZYPwc45{\XQEoIfpeIghem:vaXTldJNqdg>? M37jdlIzQDJ4NE[3
MDA-231 NEjWfFZCeG:ydH;zbZMhSXO|YYm= MXOwMlAyNTFyzszN Ml3oO|IhcA>? Mnq4SG1UVw>? MX7pcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu Mm\pNlI5OjZ2Nke=
BT-20 MmLHRZBweHSxc3nzJGF{e2G7 MYmwMlAyNTFyzszN NXroXnF6PzJiaB?= NEjKOY9FVVOR MWLpcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu NFq5XmQzOjh{NkS2Oy=>
U937 MlrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33rVlUuOjBizszN NXvseHIxOjRxNEivO|IhcA>? NGrKbFNqdmS3Y3XzJIEh\GWlcnXhd4UhcW5iY3XscEB3cWGkaXzpeJkhcW5iYTDjc45k\W62cnH0bY9vNSCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz NUjRZ2xxOjJ5NkewNlE>
HL60 MkHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIThO|M2NTJyIN88US=> MlHJNlQwPDhxN{KgbC=> MVjpcoR2[2W|IHGg[IVkemWjc3WgbY4h[2WubDD2bYFjcWyrdImgbY4h[SClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy NULhbVJZOjJ5NkewNlE>
U937 M2\GVWFxd3C2b4Ppd{BCe3OjeR?= M{DDdVE2KM7:TR?= NIL4VFQzPC92OD:3NkBp NFH1[WNqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NEi1eHEzOjd4N{CyNS=>
HL60 M4HtRWFxd3C2b4Ppd{BCe3OjeR?= NV\YeXVmOTVizszN NV\YeId{OjRxNEivO|IhcA>? NGmxbWdqdmS3Y3XzJINmdGxiYYDvdJRwe2m| M13DO|IzPzZ5MEKx
LS411N  MmLlRZBweHSxc3nzJGF{e2G7 MkHrNE42KM7:TR?= MmX5O|IhcA>? MWnpcoNz\WG|ZYOgSoF{KG2UTlGgcIV3\Wx? M4P4WlIzPDZzNkm1
MDA-MB-231 M3;NSWFxd3C2b4Ppd{BCe3OjeR?= NUP0eWxtOTBizszN NXfwUJJEPDhiaB?= NIPicZhz\WS3Y3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NYPI[mN2OjF6OEe2PVc>
MCF-7  MVzBdI9xfG:|aYOgRZN{[Xl? MXOxNEDPxE1? MlntOFghcA>? MVry[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NIPzfmkzOTh6N{[5Oy=>
A375 NYHiO|VvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV[wMlUh|ryP MUexM|UwQCCm Mn7BbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? NEnpWFgzOTd7Nk[yNi=>
SKMEL1 MnjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYW2d|F7OC53IN88US=> MnXSNU82NzhiZB?= M3vLUIlvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| NXTtbFB3OjF5OU[2NlI>
SKMEL3 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXmzVWtqOC53IN88US=> Mo\3NU82NzhiZB?= NG[wNIhqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= M2TDelIyPzl4NkKy
SKMEL28 NVzvTXZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfPNE42KM7:TR?= MoPsNU82NzhiZB?= MX\pcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? MViyNVc6PjZ{Mh?=
MeWo NXzqeYY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXmwMlUh|ryP MXqxM|UwQCCm NELBSGpqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= MVSyNVc6PjZ{Mh?=
B16 MnzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTHdWl[OC53IN88US=> M3;KNFEwPS96IHS= MXTpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? MVyyNVc6PjZ{Mh?=
Ly 1 NH74VlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NISzSmwzPCCq NXjW[W5rUUN3ME23MlMh|ryP M{nQT|IyPzd{MES5
Ly 7 M3jVWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zvbFI1KGh? MWTJR|UxRTFyLkeg{txO MYWyNVc4OjB2OR?=
Su-DHL6 NFPzUXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojRNlQhcA>? M3jkXmlEPTExvK6yNEDPxE1? NYrsfW1QOjF5N{KwOFk>
Ly 10 Ml6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzmU5JUOjRiaB?= NVn2UIREUUN3MP-8olIxKM7:TR?= MYeyNVc4OjB2OR?=
RIVA MkjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vN[VI1KGh? NXL4bmp6UUN3MP-8olIxKM7:TR?= NHvBXI8zOTd5MkC0PS=>
Su-DHL2 NI\hfnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoX6NlQhcA>? M1frdGlEPTExvK6yNEDPxE1? NWjyfHpbOjF5N{KwOFk>
Ly 1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjrWGg1QCCq NFvCXnVKSzVyPUCuN|Qh|ryP MW[yNVc4OjB2OR?=
Ly 7 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLIOFghcA>? NGH2bnBKSzVyPUCuNFI2KM7:TR?= NE[1bIwzOTd5MkC0PS=>
Su-DHL6 MkPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfpZZY1QCCq M1\FPWlEPTExvK6yNEDPxE1? M1G5c|IyPzd{MES5
Ly 10 M{XWeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\OWlQ5KGh? M{DubWlEPTB;MT64JO69VQ>? MmL4NlE4PzJyNEm=
RIVA MnTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUO0PEBp MlXRTWM2OO,:nkKwJO69VQ>? M13Hd|IyPzd{MES5
Su-DHL2 MknHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHORVA1QCCq M2L5SmlEPTB;MUeuOEDPxE1? MmexNlE4PzJyNEm=
Ly 1 NVPtbY5nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIexWII4OiCq NIiydWRKSzVyPUCuNFEh|ryP NGrZZlEzOTd5MkC0PS=>
Ly 7 NGG2SVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PsR|czKGh? Ml3uTWM2OD1yLkCxPEDPxE1? NVizNGVqOjF5N{KwOFk>
Su-DHL6 NEDzOpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPNOZE4OiCq M3iwTGlEPTB;MT62JO69VQ>? MnHlNlE4PzJyNEm=
Ly 10 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXe3NkBp M{DpW2lEPTB;MT6yJO69VQ>? MmrINlE4PzJyNEm=
RIVA NGnyfnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33X[|czKGh? M3uyR2lEPTExvK6yNEDPxE1? MVWyNVc4OjB2OR?=
Su-DHL2 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3SzdlczKGh? MYrJR|UxRTFzLkKg{txO NGXlWYEzOTd5MkC0PS=>

... Click to View More Cell Line Experimental Data

In vivo In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

Protocol

Kinase Assay:[1]
+ Expand

DNA synthesis assay :

The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
Cell Research:[1]
+ Expand
  • Cell lines: HL-60 and KG1a
  • Concentrations: 0-500 nM
  • Incubation Time: 96 hours
  • Method: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • Formulation: Decitabine is dissolved in sterile PBS .
  • Dosages: ≤2.5 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
water
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 228.21
Formula

C8H12N4O4

CAS No. 2353-33-5
Storage powder
in solvent
Synonyms Deoxycytidine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02839694 Recruiting Neoplasm Metastasis|Sarcoma|Neoplasms, Germ Cell and Embryonal|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7, 2016 Phase 1
NCT01479348 Enrolling by invitation Head and Neck Neoplasms|Lung Neoplasms|Urinary Bladder Neoplasms|Breast Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 28, 2011 Early Phase 1
NCT03041688 Not yet recruiting Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|TP53 wt Allele|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) October 2017 Phase 1
NCT03009240 Not yet recruiting Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia City of Hope Medical Center|National Cancer Institute (NCI) June 2017 Phase 1
NCT02890329 Not yet recruiting Chimerism|Hematopoietic Cell Transplantation Recipient|Myelodysplastic Syndrome With Excess Blasts-1|Myelodysplastic Syndrome With Excess Blasts-2|Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) April 2017 Phase 1
NCT02847000 Not yet recruiting Metastatic Pancreatic Adenocarcinoma Yogen Saunthararajah|Case Comprehensive Cancer Center March 2017 Early Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is S1200 a racemic mixture or a monomer?

  • Answer:

    S1200 is R form

DNA Methyltransferase Signaling Pathway Map

Tags: buy Decitabine | Decitabine supplier | purchase Decitabine | Decitabine cost | Decitabine manufacturer | order Decitabine | Decitabine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID